University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Rebecca Olin, M.D.

Blood disorder specialist

Dr. Rebecca Olin specializes in adult bone marrow transplantation (BMT) and the treatment of leukemia, lymphoma, myelodysplasia and myeloproliferative disorders, and multiple myeloma. In her research, she is particularly interested in the process of decision making in cancer treatment and the impact of cancer treatment on patient quality of life. She also studies how best to treat blood cancers in older patients.

Olin earned a medical degree at the University of Pennsylvania School of Medicine and was elected to Alpha Omega Alpha in 2002. She completed a residency in Internal Medicine and a fellowship in Hematology and Oncology, both at the Hospital of the University of Pennsylvania, and served as chief fellow from 2007 to 2008. Olin also earned a master's degree in clinical epidemiology, with a focus on medical decision making. She is an assistant clinical professor of medicine at UCSF.

Clinics

Hematology and Blood and Marrow Transplant
400 Parnassus Ave.,
Suite A-502
San Francisco, CA 94143
Existing Patients: (415) 353-2421
New Patients: (415) 353-2051

Hours: Monday to Friday
8 a.m. – 5 p.m

Conditions & Treatments

More about Rebecca Olin

Additional Languages

French

Education

University of Pennsylvannia School of Medicine 2003

Residencies

Hospital of the University of Pennsylvannia, Internal Medicine 2006

Fellowships

Hospital of the University of Pennsylvannia, Hematology-Oncology 2009

Selected Research and Publications

  1. Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol. 2014 Jul; 5(3):238-44.
  2. Olin RL, Andreadis C. David versus Goliath: decision analysis predicts results of a large clinical trial in follicular lymphoma. J Clin Oncol. 2013 Oct 1; 31(28):3608-9.
  3. Olin RL, Kanetsky PA, Ten Have TR, Nasta SD, Schuster SJ, Andreadis C. Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis. Am J Hematol. 2010 Apr; 85(4):255-60.
  4. Olin RL, Vogl DT, Porter DL, Luger SM, Schuster SJ, Tsai DE, Siegel DL, Cook RJ, Mangan PA, Cunningham K, Stadtmauer EA. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant. 2009 Mar; 43(5):417-22.
  5. Olin RL, Nichols KE, Naghashpour M, Wasik M, Shelly B, Stadtmauer EA, Vogl DT. Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis. Am J Hematol. 2008 Sep; 83(9):747-9.
  6. Olin RL, Desai SS, Fox K, Davidson R. Non-myopathic cardiac events in two patients treated with trastuzumab. Breast J. 2007 Mar-Apr; 13(2):211-2.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.